Burch R.C. Buse D.C. Lipton R.B.

Migraine: Epidemiology, Burden, and Comorbidity.

Neurol Clin. 37: 631-649Headache disorders. World Health Organization, () ()Buse D.C. Loder E.W. Gorman J.A. et al.

Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.

Headache. 53: 1278-1299Schroeder R.A. Brandes J. Buse D.C. et al.

Sex and Gender Differences in Migraine-Evaluating Knowledge Gaps.

J Womens Health (Larchmt). 27: 965-973Lyngberg A.C. Rasmussen B.K. Jørgensen T. et al.

Incidence of primary headache: a Danish epidemiologic follow-up study.

Am J Epidemiol. 161: 1066-1073Ashina M. Katsarava Z. Do T.P. et al.

Migraine: epidemiology and systems of care.

Lancet. 397: 1485-1495Allais G. Chiarle G. Sinigaglia S. et al.

Gender-related differences in migraine.

Neurol Sci. 41: 429-436Baykan B. Ertas M. Karlı N. et al.

Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey.

J Headache Pain. 16: 103Vetvik K.G. MacGregor E.A.

Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.

Lancet Neurol. 16: 76-87Burch R. Rizzoli P. Loder E.

The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.

Headache. 61: 60-68Burch R. Rizzoli P. Loder E.

The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies.

Headache. 58: 496-505Stovner L.J. Hagen K. Linde M. et al.

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.

J Headache Pain. 23: 34Safiri S. Pourfathi H. Eagan A. et al.

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019.

Pain. 163: e293-e309Chai N.C. Rosenberg J.D. Lee Peterlin B.

The epidemiology and comorbidities of migraine and tension-type headache.

Tech Reg Anesth Pain Manag. 16: 4-13MacGregor E.A. Frith A. Ellis J. et al.

Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen.

Neurology. 67: 2154-2158

Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review.

Headache. 60: 200-216Goadsby P.J. Holland P.R. Martins-Oliveira M. et al.

Pathophysiology of Migraine: A Disorder of Sensory Processing.

Physiol Rev. 97: 553-622Ferrari M.D. Goadsby P.J. Burstein R. et al.

Migraine.

Nat Rev Dis Primers. 8: 2Cui Y. Kataoka Y. Watanabe Y.

Role of cortical spreading depression in the pathophysiology of migraine.

Neurosci Bull. 30: 812-822

Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain.

Pain. 154: S44-S53de Vries Lentsch S. Rubio-Beltran E. MaassenVanDenBrink A.

Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications.

Maturitas. 145: 73-77Eikermann-Haerter K. Kudo C. Moskowitz M.A.

Cortical spreading depression and estrogen.

Headache. 47: S79-S85Bolay H. Berman N.E. Akcali D.

Sex-related differences in animal models of migraine headache.

Headache. 51: 891-904Aegidius K. Zwart J.A. Hagen K. et al.

The effect of pregnancy and parity on headache prevalence: the Head-HUNT study.

Headache. 49: 851-859van Oosterhout W.P.J. Schoonman G.G. van Zwet E.W. et al.

Female sex hormones in men with migraine.

Neurology. 91: e374-e381Aloisi A.M. Bachiocco V. Costantino A. et al.

Cross-sex hormone administration changes pain in transsexual women and men.

Pain. 132: S60-S67

Migraine prevalence in male to female transsexuals on hormone therapy.

Neurology. 63: 593-594Martin V.T. Wernke S. Mandell K. et al.

Defining the relationship between ovarian hormones and migraine headache.

Headache. 45: 1190-1201Allais G. Chiarle G. Bergandi F. et al.

The use of progestogen-only pill in migraine patients.

Expert Rev Neurother. 16: 71-82

Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version).

Cephalalgia. 33: 629-808

Ovarian hormones and pain response: a review of clinical and basic science studies.

Gend Med. 6: 168-192Granella F. Sances G. Allais G. et al.

Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres.

Cephalalgia. 24: 707-716

Sex-related differences in migraine.

Neurol Sci. 35: 207-213Pavlovic J.M. Allshouse A.A. Santoro N.F. et al.

Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles.

Neurology. 87: 49-56

The role of estradiol withdrawal in the etiology of menstrual migraine.

Neurology. 22: 355-365Nyholt D.R. van den Maagdenberg A.M.

Genome-wide association studies in migraine: current state and route to follow.

Curr Opin Neurol. 29: 302-308Gormley P. Anttila V. Winsvold B.S. et al.

Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine.

Nat Genet. 48: 856-866Sutherland H.G. Griffiths L.R.

Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders.

Headache. 57: 537-569Abanoz Y. Gulen Abanoz Y. Gunduz A. et al.

Migraine as a risk factor for young patients with ischemic stroke: a case-control study.

Neurol Sci. 38: 611-617Kurth T. Winter A.C. Eliassen A.H. et al.

Migraine and risk of cardiovascular disease in women: prospective cohort study.

BMJ. 353: i2610Adelborg K. Szepligeti S.K. Holland-Bill L. et al.

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.

BMJ. 360: k96Kurth T. Gaziano J.M. Cook N.R. et al.

Migraine and risk of cardiovascular disease in women.

JAMA. 296: 283-291Kurth T. Schurks M. Logroscino G. et al.

Migraine, vascular risk, and cardiovascular events in women: prospective cohort study.

BMJ. 337: a636MacClellan L.R. Giles W. Cole J. et al.

Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study.

Stroke. 38: 2438-2445Schurks M. Rist P.M. Bigal M.E. et al.

Migraine and cardiovascular disease: systematic review and meta-analysis.

BMJ. 339: b3914Champaloux S.W. Tepper N.K. Monsour M. et al.

Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke.

Am J Obstet Gynecol. 216: 489 e481-489 e487Fazio G. Ferrara F. Barbaro G. et al.

Protrhombotic effects of contraceptives.

Curr Pharm Des. 16: 3490-3496ACOG Practice Bulletin No. 206

Use of Hormonal Contraception in Women With Coexisting Medical Conditions.

Obstet Gynecol. 133: e128-e150

Gender considerations in stroke management.

Neurol. 15: 132-141Scher A.I. Gudmundsson L.S. Sigurdsson S. et al.

Migraine headache in middle age and late-life brain infarcts.

JAMA. 301: 2563-2570Palm-Meinders I.H. Koppen H. Terwindt G.M. et al.

Structural brain changes in migraine.

JAMA. 308: 1889-1897

How do you feel–now? The anterior insula and human awareness.

Nat Rev Neurosci. 10: 59-70

SEEDS for success: Lifestyle management in migraine.

Cleve Clin J Med. 86: 741-749Wells R.E. O'Connell N. Pierce C.R. et al.

Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial.

JAMA Intern Med. 181: 317-328

Efficacy of biofeedback for migraine: a meta-analysis.

Pain. 128: 111-127Bae J.Y. Sung H.K. Kwon N.Y. et al.

Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis.

Medicina (Kaunas). 58: 44Mallick-Searle T. Moriarty M.

Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists: An integrative review.

J Am Assoc Nurse Pract. 33: 419-428Agostoni E.C. Barbanti P. Calabresi P. et al.

Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

J Headache Pain. 20: 92VanderPluym J.H. Halker Singh R.B. Urtecho M. et al.

Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.

JAMA. 325: 2357-2369Thorlund K. Toor K. Wu P. et al.

Comparative tolerability of treatments for acute migraine: A network meta-analysis.

Cephalalgia. 37: 965-978Lipton R.B. Buse D.C. Serrano D. et al.

Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.

Headache. 53: 1300-1311Holland P.R. Goadsby P.J.

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Neurotherapeutics. 15: 304-312

Lasmiditan for acute treatment of migraine.

Drugs Today. 57: 89-100

Acute Treatment of Migraine.

Neurol Clin. 37: 727-742Moisset X. Pereira B. Ciampi de Andrade D. et al.

Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials.

J Headache Pain. 21: 142Schwedt T.J. Hentz J.G. Sahai-Srivastava S. et al.

Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial.

Neurology. 98: e1409-e1421Ailani J. Burch R.C. Robbins M.S.

Board of Directors of the American Headache S. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.

Headache. 61: 1021-1039Dolati S. Rikhtegar R. Mehdizadeh A. et al.

The Role of Magnesium in Pathophysiology and Migraine Treatment.

Biol Trace Elem Res. 196: 375-383D'Onofrio F. Raimo S. Spitaleri D. et al.

Usefulness of nutraceuticals in migraine prophylaxis.

Neurol Sci. 38: 117-120Hepp Z. Dodick D.W. Varon S.F. et al.

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.

Cephalalgia. 37: 470-485Argyriou A.A. Dermitzakis E.V. Vlachos G.S. et al.

Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis.

Acta Neurol Scand. 145: 676-683Croop R. Lipton R.B. Kudrow D. et al.

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.

Lancet. 397: 51-60Ailani J. Lipton R.B. Goadsby P.J. et al.

Atogepant for the Preventive Treatment of Migraine.

N Engl J Med. 385: 695-706Deng H. Li G.G. Nie H. et al.

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.

BMC Neurol. 20: 57Varnado O.J. Manjelievskaia J. Ye W. et al.

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.

Patient Prefer Adherence. 16: 821-839Negro A. Sciattella P. Rossi D. et al.

Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre.

J Headache Pain. 20: 120Lipton R.B. Munjal S. Alam A. et al.

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.

Headache. 58: 1408-1426

Gender Differences in the Use of Complementary and Alternative Medicine and Their Association With Moderate Mental Distress in U.S. Adults With Migraines/Severe Headaches.

Headache. 57: 97-108Korolainen M.A. Kurki S. Lassenius M.I. et al.

Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care.

J Headache Pain. 20: 13Humphries K.H. Pu A. Gao M. et al.

Angina with "normal" coronary arteries: sex differences in outcomes.

Am Heart J. 155: 375-381MaassenVanDenBrink A. Meijer J. Villalon C.M. et al.

Wiping Out CGRP: Potential Cardiovascular Risks.

Trends Pharmacol Sci. 37: 779-788Petersen K.A. Birk S. Lassen L.H. et al.

The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers.

Cephalalgia. 25: 139-147Depre C. Antalik L. Starling A. et al.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.

Headache. 58: 715-723Allais G. Chiarle G. Sinigaglia S. et al.

Menstrual migraine: a review of current and developing pharmacotherapies for women.

Expert Opin Pharmacother. 19: 123-136Maasumi K. Tepper S.J. Kriegler J.S. et al.

Menstrual Migraine, Review.

Headache. 57: 194-208Mannix L.K. Martin V.T. Cady R.K. et al.

Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials.

Obstet Gynecol. 114: 106-113Bigal M. Sheftell F. Tepper S. et al.

A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine.

Headache. 48: 1286-1293Allais G. Bussone G. Tullo V. et al.

Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial.

Cephalalgia. 35: 45-50Brandes J.L. Poole A. Kallela M. et al.

Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.

Cephalalgia. 29: 1133-1148MacGregor E.A. Brandes J.L. Silberstein S. et al.

Safety and tolerability of short-term preventive frovatriptan: a combined analysis.

Headache. 49: 1298-1314Newman L.C. Lipton R.B. Lay C.L. et al.

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.

Neurology. 51: 307-309Tuchman M.M. Hee A. Emeribe U. et al.

Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.

CNS Drugs. 22: 877-886Mannix L.K. Savani N. Landy S. et al.

Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.

Headache. 47: 1037-1049Marcus D.A. Bernstein C.D. Sullivan E.A. et al.

Perimenstrual eletriptan prevents menstrual migraine: an open-label study.

Headache. 50: 551-562Sances G. Martignoni E. Fioroni L. et al.

Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.

Headache. 30: 705-709Allais G. Bussone G. De Lorenzo C. et al.

Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations.

Neurol Sci. 28: S225-S228Facchinetti F. Sances G. Borella P. et al.

Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium.

Headache. 31: 298-301de Lignieres B. Vincens M. Mauvais-Jarvis P. et al.

Prevention of menstrual migraine by percutaneous oestradiol.

Br Med J. 293: 1540MacGregor E.A. Frith A. Ellis J. et al.

Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.

Neurology. 67: 2159-2163Coffee A.L. Sulak P.J. Hill A.J. et al.

Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines.

J Womens Health (Larchmt). 23: 310-317Sulak P. Willis S. Kuehl T. et al.

Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.

Headache. 47: 27-37Robbins M.S. Farmakidis C. Dayal A.K. et al.

Acute headache diagnosis in pregnant women: a hospital-based study.

Neurology. 85: 1024-1030LaHue S.C. Gelfand A.A. Bove R.M.

Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?.

Neurology. 93: 668-672Parikh S.K. Delbono M.V. Silberstein S.D.

Managing migraine in pregnancy and breastfeeding.

Prog Brain Res. 255: 275-309Childress K.M.S. Dothager C. Gavard J.A. et al.

Metoclopramide and Diphenhydramine: A Randomized Controlled Trial of a Treatment for Headache in Pregnancy when Acetaminophen Alone Is Ineffective (MAD Headache Study).

Am J Perinatol. 35: 1281-1286Dudman D.C. Tauqeer F. Kaur M. et al.

A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project.

J Neurol. 269: 742-749Magro I. Nurimba M. Doherty J.K.

Headache in Pregnancy.

Otolaryngol Clin North Am. 55: 681-696

Noninvasive Neuromodulation in Migraine.

Curr Pain Headache Rep. 24: 78Wells R.E. Turner D.P. Lee M. et al.

Managing Migraine During Pregnancy and Lactation.

Curr Neurol Neurosci Rep. 16: 40

Migraine in pregnancy and lactation.

Neurol Sci. 35: 61-64Brin M.F. Kirby R.S. Slavotinek A. et al.

Pregnancy outcomes following exposure to onabotulinumtoxinA.

Pharmacoepidemiol Drug Saf. 25: 179-187

Headache in Pregnancy, the Puerperium, and menopause.

Semin Neurol. 38: 627-633

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.

Cephalalgia. 39: 445-458Datta P. Rewers-Felkins K. Kallem R.R. et al.

Transfer of Low Dose Aspirin Into Human Milk.

J Hum Lact. 33: 296-299Hutchinson S. Marmura M.J. Calhoun A. et al.

Use of common migraine treatments in breast-feeding women: a summary of recommendations.

Headache. 53: 614-627Pancheri C. Maraone A. Roselli V. et al.

The role of stress and psychiatric comorbidities as targets of non-pharmacological therapeutic approaches for migraine.

Riv Psichiatr. 55: 262-268Klenofsky B. Pace A. Natbony L.R. et al.Curr Pain Headache Rep. 23: 1

Sex Differences in Insomnia: from Epidemiology and Etiology to Intervention.

Curr Psychiatry Rep. 20: 69

Why Are Women Prone to Restless Legs Syndrome?.

Int J Environ Res Public Health. 17: 368Tiseo C. Vacca A. Felbush A. et al.

Migraine and sleep disorders: a systematic review.

J Headache Pain. 21: 126Fang X. Patel C. Gudesblatt M.

Multiple Sclerosis: Clinical Updates in Women's Health Care Primary and Preventive Care Review.

Obstet Gynecol. 135: 757-758Gerosa M. De Angelis V. Riboldi P. et al.

Rheumatoid arthritis: a female challenge.

Womens Health (Lond). 4: 195-201Zucchi D. Elefante E. Calabresi E. et al.

One year in review 2019: systemic lupus erythematosus.

Clin Exp Rheumatol. 37: 715-722Breen I.D. Brumfiel C.M. Patel M.H. et al.

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.

JAMA Netw Open. 4: e217934Gerard A.O. Merino D. Van Obberghen E.K. et al.

Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.

J Headache Pain. 23: 53

The role of gender in fibromyalgia syndrome.

Curr Rheumatol Rep. 3: 128-134Fichera G. Polizzi A. Scapellato S. et al.

Craniomandibular Disorders in Pregnant Women: An Epidemiological Survey.

J Funct Morphol Kinesiol. 5: 36

Sex-Gender Differences in Irritable Bowel Syndrome.

J Neurogastroenterol Motil. 24: 544-558Goncalves D.A. Camparis C.M. Speciali J.G. et al.

Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study.

J Orofac Pain. 27: 325-335Marcus D.A. Bernstein C. Rudy T.E.

Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome.

Clin Rheumatol. 24: 595-601

Effects on migraine, neck pain, and head and neck posture, of temporomandibular disorder treatment: Study of a retrospective cohort.

Arch Oral Biol. 114: 104718Xie Y. Zhou G. Xu Y. et al.

Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome.

Pain Res Manag. 2019: 7890461

Migraine: Stigma in Society.

Curr Pain Headache Rep. 23: 8Young W.B. Park J.E. Tian I.X. et al.

The stigma of migraine.

PLoS One. 8: e54074